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Abstract
Background/Aims: Pancreatic ductal adenocarcinoma 
(PDAC) is characterized by aggressive invasion, early metas-
tasis, and resistance to chemotherapy, leading to a poor 
prognosis. To clarify the molecular mechanism of these ma-
lignant characteristics, we performed a genome-wide mi-
croRNA (miRNA) array analysis utilizing micro-cancer tissues 
from patients with unresectable PDAC (stage IV), obtained 
by endoscopic ultrasound-fine needle aspiration (EUS-FNA). 
Methods: The expression profiles of 2,042 miRNAs were de-
termined using micro-cancer tissues from 13 patients with 
unresectable PDAC obtained by EUS-FNA. The relationship 
between individual miRNA levels and overall survival (OS) 
was analyzed. Possible target genes for miRNAs were bioin-
formatically analyzed using the online database miRDB. Pan-
creatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were 
transfected with miRNA mimic or small interfering RNA, and 
cell invasion, epithelial-mesenchymal transition (EMT), and 
apoptosis markers were examined. miRNA and mRNA ex-
pressions were examined by quantitative polymerase chain 
reaction. Results: Of 2,042 miRNAs, the 10 that exhibited the 
lowest correlation coefficient (p ≤ 0.005) between miRNA ex-
pression level and OS among the patients were identified. 
The miRDB and expression analysis in cancer cell lines for the 
10 miRNAs identified miR-296-5p and miR-1207-5p as bio-
markers predictive of shorter survival (p < 0.0005). Bioinfor-
mative target gene analysis and transfection experiments 
with miRNA mimics showed that Bcl2-related ovarian killer 
(BOK), a pro-apoptotic gene, is a target for miR296-5p in pan-
creatic cancer cells; transfection of miR-296-5p mimic into 
PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant 
suppression of BOK mRNA and protein expression. These 
transfectants showed significantly higher invasion capabili-
ty compared with control cells, and knock down of BOK in 
pancreatic cancer cells similarly enhanced invasion capabil-
ity. Transfectants of miR-296-5p mimic also exhibited aber-
rant expression of EMT markers, including vimentin and N-
cadherin. Moreover, these transfectants showed a signifi-
cantly lower apoptosis rate in response to 5-fluorouracil and 
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gemcitabine with a decrease of BOK expression, suggesting 
a role of miR-296-5p in drug resistance. Conclusion: These 
results suggest that miR-296-5p is a useful biomarker for a 
poor prognosis in patients with PDAC, and that the miR-296-
5p/BOK signaling axis plays an important role in cell inva-
sion, drug resistance, and EMT in PDACs.
© 2019 S. Karger AG, Basel
Introduction
Despite recent improvements in diagnostic and thera-
peutic strategies, pancreatic cancer remains a major cause 
of cancer-related death worldwide [1]. The current 5-year 
survival rate for pancreatic cancer patients is < 10% [2]. 
Pancreatic ductal adenocarcinoma (PDAC), a common 
type of pancreatic cancer, is characterized by aggressive 
local invasion, early metastasis, and resistance to chemo-
therapy. Moreover, it has recently been reported that ep-
ithelial-mesenchymal transition (EMT) of cancer cells is 
associated with acquisition of invasion ability, drug resis-
tance, and enhanced cell proliferation. To improve the 
prognosis of PDAC, it is essential to clarify the molecular 
mechanisms that contribute to the underlying malignan-
cy and to find molecular targets for the development of 
therapeutic and diagnostic strategies.
MicroRNAs (miRNAs) are endogenous small non-
coding RNA molecules of 20–25 nucleotides that regulate 
the expression of target genes through transcription and/
or translation [3, 4]. miRNAs play an important role in 
carcinogenesis, metastasis, and invasion in various types 
of cancers including pancreatic cancer [5, 6]. Moreover, 
recent advances in microarray technologies have made 
it  possible to measure the global expression of > 1,000 
 miRNAs simultaneously [7]. Using this method, several 
studies have detected specific miRNAs related to the 
pathogenesis of pancreatic cancer [8–13]. However, most 
of these studies have used surgically-operated PDAC tis-
sues for analyses of miRNA and/or mRNAs because in-
operative metastatic PDAC tissues were not available. 
That is, only operable PDAC tissues, which show no me-
tastasis, drug resistance, or EMT, have been examined 
thus far in efforts to identify useful molecular biomarkers 
and therapeutic targets.
Recently, endoscopic ultrasonography (EUS) and 
EUS-guided fine needle aspiration (EUS-FNA) sampling 
of pancreatic tumors have become popular procedures 
worldwide [14, 15]. In clinical practice, EUS-FNA is safe-
ly and easily performed for pathological diagnosis of not 
only early pancreatic cancer but also of inoperable meta-
static pancreatic cancer. Although the amount of cancer 
tissue obtained by EUS-FNA is very small, we confirmed 
in our preliminary experiments that the amount of cancer 
tissue obtained by EUS-FNA was sufficient for miRNA 
array analysis. Therefore, in this study, we first performed 
a genome-wide miRNA array analysis using micro-tis-
sues obtained by EUS-FNA to find useful prognostic bio-
markers for unresectable advanced PDAC. We ultimate-
ly identified miR-296-5p as a specific prognostic marker 
for PDAC and examined its target genes and potential 
role in invasion, EMT, anti-apoptotic resistance, and pro-
liferation in PDAC.
Patients and Methods
Human Tissue Specimens
This study was approved by the Ethics Committee of Tokushi-
ma University Hospital (Approval number; 1845). Thirteen pa-
tients with pancreatic tumors, suspected as advanced pancreatic 
cancer based on CT, were recruited at Tokushima University 
Hospital. After obtaining written informed consent, 3 tumor 
specimens per patient were obtained by EUS-FNA technique 
with a 22- or 25-gauge needle; 2 were fixed for pathological di-
agnosis and 1 was frozen at –80   ° C for RNA analysis. All the 
touch smears were stained using Diff-Quick (Mercedes Medical, 
Sarasota, FL, USA) to evaluate tumor cell morphology. Hema-
toxylin and eosin staining was performed to confirm pathological 
diagnosis of pancreatic cancer. All patients were definitely diag-
nosed as having unresectable PDAC and were enrolled in the 
study. Baseline characteristics of the patients are shown in Table 
1. All patients were at clinical stage IV, had not undergone surgi-
cal resection, and had received chemotherapy after the diagnosis 
of PDAC. The disease response to treatment was defined accord-
ing to the Response Evaluation Criteria in Solid Tumors version 
1.1 [16].
Cell Lines and Culture Condition
Five human pancreatic cancer cell lines were used. PANC-1 
and MIA PaCa-2 cell lines were purchased from the American 
Type Culture Collection (Manassas, VA, USA). PK-1, PK-8, and 
PK-45H cell lines were purchased from RIKEN Cell Bank (Kobe, 
Japan). PANC-1 cells were cultured in Dulbecco’s Modified Ea-
gle’s medium (DMEM) containing 10% fetal bovine serum (FBS). 
MIA PaCa-2 cells were cultured in DMEM containing 10% FBS 
and 2.5% horse serum. PK-1, PK-8, and PK-45H were cultured in 
RPMI-1640 medium containing 10% FBS.
RNA Extraction and miRNA Microarray
Total RNA including the miRNA fraction was extracted from 
EUS-FNA samples and pancreatic cancer cell lines using a miR-
Neasy Mini Kit (Qiagen, Hilden, Germany). The concentration of 
RNA was measured with a NanoDrop 1000 spectrophotometer 
(NanoDrop Technologies; Thermo Scientific), and the quality of 
the purified RNA was confirmed by measuring RNA integrity with 
an Agilent 2100 Bioanalyzer and RNA 6000 LabChip Kit (Agilent 
Technologies, Palo Alto, CA, USA).
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A human miRNA microarray (GPL18402; based on Sanger 
miRbase release 19.0; Agilent Technologies) was used for mea-
suring global miRNA expression in PDCA tissues. Total RNA 
was labeled with cyanine 3-cytidine bisphosphate using T4 ligase 
and hybridized to a SurePrint G3 human miRNA microarray 
using miRNA complete labeling reagent and a hybridization kit 
(Agilent Technologies). Subsequently, each sample was scanned 
using a Microarray Scanner (G2505C; Agilent Technologies), 
and fluorescence signals were analyzed using Feature Extrac-
tion  Software (version 10.7.3.1). Raw intensity miRNA data 
were analyzed using GeneSpring GX 12 software (Agilent Tech-
nologies). The complete datasets were deposited in the Gene Ex-
pression Omnibus database with an accession number of 
GSE109918.
In Silico Identification of miRNA Target Genes
To bioinformatically predict target genes based on the miRNA 
seed sequence, we used miRDB (http://mirdb.org/), an online da-
tabase for miRNA target prediction and functional annotations 
[17].
Quantitative Real-Time Polymerase Chain Reaction
miRNA expression was measured by using TaqMan miRNA 
Assay (Applied Biosystems, Foster City, CA, USA). RNU48 sn-
RNA was used as an internal quantity control for normalization. 
The assay numbers of the TaqMan miRNA reagents were as fol-
lows: hsa-miR-296-5p (#000527), hsa-miR-516a-5p (#002416), 
hsa-miR-557 (#001525), hsa-miR-1207-5p (#241060), hsa-miR-
4740-5p (#462027), and RNU48 (#001006). Relative expression 
levels of miRNA in each sample were measured by using the delta-
delta Ct method.
The mRNA levels of 4 predicted target genes (Bcl2-related ovar-
ian killer [BOK], NUMBL, CD276, and ATP11A) were determined 
using Power SYBR green polymerase chain reaction (PCR) Master 
Mix (Applied Biosystems) and an ABI 7,500 real-time PCR system 
(Applied Biosystems). The primer sequences used are shown in on-
line supplementary Table S1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000503225). Glyceraldehyde 3-phosphate 
dehydrogenase mRNA was used as an endogenous quantitative con-
trol, and the relative expression levels of mRNA in each sample were 
measured by using the delta-delta Ct method.
Transfection of miRNA Mimics
miR-296-5p and miR-1207-5p mimic (mirVana miRNA mim-
ic; Life Technologies) were used for transfection into pancreatic 
cancer cell lines. PANC-1, MIA PaCa-2, and PK-8 cells (1.0 × 104) 
plated in 6-well plates were transfected with miR-296-5p or 
 miR-1207-5p mimic (mirVana miRNA mimic; Life Technologies) 
at a final concentration of 30 nM using Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA, USA) in Opti-MEM medium (Gibco, 
Life Technologies, Gaithersburg, MD, USA). mirVana miRNA 
Mimic, Negative Control #1 (Life Technologies) was used as a neg-
ative control miRNA.
Gene Knockdown Using Small Interfering RNA
Specific double-stranded, small interfering RNA (siRNA) tar-
geting BOK (Silencer Select s194313; Ambion, Austin, TX, USA; 
sense, 5′-GCAAGGUGGUGUCCCUGUAtt-3′; antisense, 5′-UA-
CAGGGACACCACCUUGCcc-3′) was transfected into PANC-1 
cells using Lipofectamine RNAiMAX (Invitrogen) according to 
the manufacturer’s instructions. Silencer Negative Control #1 siR-
NA (AM4611; Ambion) was used as a negative control.
Cell Proliferation and Invasion Assays
For the proliferation assay, PANC-1 and MIA PaCa-2 cells 
were transfected with an miRNA mimic or negative control and 
then plated in a 96-well plate for incubation in DMEM medium 
with 10% FBS. Viable cells were counted at 6, 24, 48, 72, and 96 h 
using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, 
Japan).
Cell invasion assays were performed using a CytoSelect 24-
well cell invasion assay kit (Cell BioLab, San Diego, CA, USA) 
according to the manufacturer’s instructions. PANC-1 and MIA 
PaCa-2 cells transfected with miRNA mimic or control mimic 
Table 1.  Characteristics of 13 patients of unresectable PDAC
No. Age,
years
Gender Histology Location Treatment cStage Survival 
period, months
Prognosis
1 62 Male Adenocarcinoma Body, tail S-1 IVa 22 Alive
2 60 Female Adenocarcinoma Body, tail SOXIRI IVa 20 Dead
3 62 Male Adenocarcinoma Body, tail SOXIRI IVb 19 Dead
4 80 Female Adenocarcinoma Head S-1 IVa 16 Alive
5 51 Female Adenocarcinoma Body, tail GEM IVb 12 Dead
6 43 Female Adenocarcinoma Head SOXIRI IVa 9 Dead
7 66 Male Adenocarcinoma Body, tail GEM, nab-PTX IVb 9 Dead
8 72 Female Adenocarcinoma Tail SOXIRI IVb 8 Dead
9 86 Male Adenocarcinoma Tail S-1 IVb 8 Dead
10 67 Female Adenocarcinoma Body GEM, nab-PTX IVb 6 Dead
11 68 Male Adenocarcinoma Body S-1 IVb 6 Dead
12 80 Female Adenocarcinoma Tail GEM IVb 5 Dead
13 67 Male Adenocarcinoma Body GEM, S-1 IVb 4 Dead
PDAC, pancreatic ductal adenocarcinoma; SOXIRI, S-1, oxaliplatin, and irinotecan; GEM, gemcitabine; nab-PTX, nab-paclitaxel.
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were re-suspended in culture medium without FBS and placed in 
the upper chamber in triplicate. The upper surface of the insert 
membrane is coated with a uniform layer of dried basement 
membrane matrix solution. This basement membrane layer serves 
as a barrier to discriminate invasive cells from non-invasive cells. 
The non-invasive cells were removed from the top of the mem-
brane and the invasive cells were stained and quantified. After 
48 h incubation at 37  ° C, cells migrating through the membrane 
were stained, lysed, and quantified by measuring the optical den-
sity at 560 nm.
Western Blotting
Western blotting was performed, as previously described 
[18]. Briefly, cells were lysed in RIPA buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% 
sodium dodecyl sulfate) containing protease inhibitors (Sigma-
Aldrich St. Louis, MO, USA), and the protein concentration was 
measured. Cell lysates were resolved by sodium dodecyl sulfate-
polyamide gel electrophoresis and transferred to polyvinylidene 
fluoride membranes. Blots were blocked with 5% fat-free dry 
milk in Tris-buffered saline-0.1% Tween and incubated with pri-
mary antibodies. The primary antibodies used were as follows: 
rabbit anti-human BOK monoclonal antibody (Abcam; 
ab186745), rabbit anti-human caspase-9 polyclonal antibody 
(Cell Signaling; #9502), rabbit anti-human E-cadherin poly-
clonal antibody (Cell Signaling; #3195), rabbit anti-human N-
cadherin monoclonal antibody (Cell Signaling; #13116), rabbit 
anti-human vimentin monoclonal antibody (Cell Signaling; #5741), and mouse anti-human-β-actin monoclonal antibody 
(Sigma-Aldrich; A5441).
The membranes were then incubated with secondary horserad-
ish-conjugated goat anti-rabbit antibody (GE Healthcare, UK Ltd., 
Buckinghamshire, UK), and the proteins were visualized by stan-
dard procedures including an ECL detection system (GE Health-
care UK Ltd.). β-actin was used as an internal control.
Statistical Analysis
Experimental data were analyzed using SPSS version 12.0 
(SPSS, Inc., Chicago, IL, USA). Correlations between microarray 
raw signals and the overall survival (OS) for each patient were as-
sessed using Pearson’s correlation test. Data from the invasion as-
say and proliferation assay were analyzed using Student t test. Sur-
vival analysis was performed with the Kaplan-Meier method, and 
the log-rank test was used to compare OS between high and low 
expression groups of miRNAs. GraphPad Prism version 8.0 
(GraphPad Software, Inc., La Jolla, CA, USA) was used for this 
analysis.
Results
Correlation between Individual miRNA Levels and OS 
in Patients with PDAC
In this study, we obtained small cancer tissues by EUS-
FNA from 13 patients with PDAC and extracted total 
RNAs (online suppl. Table S2). The clinical characteris-
tics of the patients are described in Table 1. Total RNAs 
were obtained in appreciable amounts and were of 
 sufficient purity for miRNA array analysis (online suppl. 
Fig. S1).
Expression profiles for 2,042 miRNAs from the 13 
PDAC specimens were successfully obtained. Correla-
tions between individual miRNA expression levels and 
the OS (months) were then analyzed for 13 patients. 
Among the 2,042 miRNAs, the 10 miRNAs that showed 
the lowest correlation coefficients (ranging from –0.790 
to –0.721) and the lowest p values (under 0.005; Table 
2) were selected. Representative plots for 5 miRNAs 
(miR-296-5p, miR-516a-5p, miR-557, miR-1207-5p, 
and miR-4740-5p) that showed correlations between 
miRNA expression and survival time are shown in Fig-
ure 1.
Predicted Target Genes of Candidate miRNAs
Possible target genes for the 10 selected miRNAs 
were examined using the miRDB. Unexpectedly, 4 of 
these miRNAs (miR-6500-5p, miR-6088, miR-887, and 
miR-1249) did not show the predicted target gene in 
the miRDB. Moreover, the sequence for miR-3620 
was not suitable for the design of TaqMan PCR probes 
in the following series of experiments. Therefore, we 
present candidate target genes of the top 5 miRNAs 
(miR-296-5p, miR-516a-5p, miR-557, miR-1207-5p, 
and miR-4740-5p) identified by miRDB analysis in Ta-
ble 3. Notably, the scores for the target genes of miR-
296-5p, miR-557, miR-1207-5p, and miR-4740-5p were 
> 95.
Table 2. Top 10 miRNAs related to the prognosis in PDAC pa-
tients
miRNA Correlation coefficient p value
hsa-miR-3620-3p –0.790 0.001
hsa-miR-296-5p –0.749 0.003
hsa-miR-6500-5p –0.735 0.004
hsa-miR-516a-5p –0.735 0.004
hsa-miR-557 –0.733 0.004
hsa-miR-1207-5p –0.731 0.005
hsa-miR-6088 –0.729 0.005
hsa-miR-887 –0.728 0.005
hsa-miR-4740-5p –0.721 0.005
hsa-miR-1249 –0.721 0.005
Pearson’s correlation coefficients were calculated from the va-
lues between the microarray data and the OS periods. 
Bold faces are representative 5 miRNAs for the further analysis.
miRNA, microRNA; PDAC, pancreatic ductal adenocarcino-
ma; OS, overall survival.
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Validation of miRNA Expressions in Pancreatic 
Cancer Cell Lines
The expression levels of the 5 miRNAs in 5 pancre-
atic cancer cell lines (PANC-1, MIA PaCa-2, PK-1, 
 PK-8, and PK-45H) were examined using the Taq-
Man  quantitative PCR (qPCR) method. The expres-
sion  levels of miR-1207-5p were high in all cell lines 
(Fig.  2). Expression of miR-296-5p was high in MIA 
PaCa-2, PK-8, and PK-45H cells but not in PANC-1 
and PK-1 cells. Expression of miR-516a-5p, miR-557, 
and miR-4740-5p was relatively low or not detected, 
suggesting the possibility that their cellular function 
was lower in the 5 cancer cell lines. Thus, we focused 
on miR-296-5p and miR-1207-5p in the following ex-
periments.
Correlation of miR-296-5p and miR-1207-5p 
Expression with OS
We also examined correlations of miR-296-5p and 
miR-1207-5p expression with OS in 13 PDAC patients 
using the Kaplan-Meier method (online suppl. Fig. S2). 
Based on the expression intensity of the miR-296-5p in 13 
cancer tissues (Fig. 1), we categorized 11 and 2 patients 
into high and low miR-296-5p groups, respectively. The 
OS of the low miR-296-5p group was significantly longer 
than that of high-miR-296-5p group (p = 0.031; online 
suppl. Fig. S2a). Similarly, we categorized 4 and 9 patients 
into low and high miR-1207-5p groups, respectively. The 
OS of the low miR-1207-5p group was significantly lon-
ger than that of the high miR-1207-5p group (p = 0.002; 
online suppl. Fig. S2b).
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Fig. 1. Negative correlations between the 
expression of 5 miRNAs and survival pe-
riod in 13 unresectable PDAC patients. Us-
ing genome-wide miRNA arrays, the ex-
pression of 2,042 miRNAs was analyzed in 
13 micro-pancreatic cancer tissues by 
 EUS-FNA. Correlations between miRNA 
expression and the OS (months) were cal-
culated using Pearson’s correlation coeffi-
cient. The results for 5 representative 
miRNAs (miR-296-5p, miR-516a-5p, miR-
557, miR-1207-5p, and miR-4740-5p) are 
shown. For each of the miRNAs, p values 
were calculated using Pearson’s test. R in-
dicates the coefficient of determination.
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Table 3. Predicted target gene of miRNAs by miRDB
miRNA Gene symbol Description Score
has-miR-296-5p BOK BOK 99
NUMBL NUMB like, endocytic adaptor protein 97
AMMECR1L AMMECR1 like 96
ZMYM3 Zinc finger MYM-type containing 3 96
CYB5R3 Cytochrome B5 reductase 3 96
has-miR-516a-5p TMEM68 Transmembrane protein 68 79
PIK3R4 Phosphoinositide-3-kinase regulatory subunit 4 74
FAM200B Family with sequence similarity 200 member B 72
TXNRD3 Thioredoxin reductase 3 68
HAUS6 HAUS augmin-like complex subunit 6 65
has-miR-557 ZER1 Zyg-11 related cell cycle regulator 100
RBMS3 RNA binding motif single stranded interacting protein 3 100
SCN1A Sodium voltage-gated channel alpha subunit 1 100
BACH2 BTB domain And CNC homolog 2 100
CLOCK Clock circadian regulator 99
has-miR-1207-5p CD276 CD276 molecule 100
ATP11A ATPase phospholipid transporting 11A 100
CBX6 Chromobox 6 100
TMEM201 Transmembrane protein 201 100
SLC6A9 Solute carrier family 6 member 9 100
has-miR-4740-5p ACLY ATP citrate lyase 99
ATG12 Autophagy related 12 99
SPTLC2 Serine palmitoyltransferase long chain base subunit 2 97
MLEC Malectin 96
AGAP1 ArfGAP with GTPase domain, ankyrin repeat And PH domain 1 96
miRNA, microRNA; BOK, Bcl-2 related ovarian killer.
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Fig. 2. Expression levels of miR-296-5p, 
miR-516a-5p, miR-557, miR-1207-5p, and 
miR-4740-5p in 5 pancreatic cancer cell 
lines. Expression levels of each miRNA in 
PANC-1, MIA PaCa-2, PK-1, PK-8, and 
PK-45H cells were determined by TaqMan 
qPCR. Relative expression levels are shown 
as the value normalized to RNU48.  miRNA, 
microRNA.
Co
lor
 ve
rsi
on
 av
ail
ab
le 
on
lin
e
miRNA-296-5p and BOK in Pancreatic 
Cancer
7Digestion
DOI: 10.1159/000503225
Altered Expression of Target Genes by miR-296-5p
To investigate whether miR-296-5p and miR-1207-5p 
regulate their candidate target genes in pancreatic cancer 
cells, we transfected their mimics into the cell lines and 
examined the target gene mRNA levels using SYBR green 
qPCR. Among the target genes for miR-296-5p, BOK and 
NUMBL (NUMB like, endocytic adaptor protein) were 
selected based on their known functions in cancer cells 
[19, 20] and predicted high scores in the miRDB (Table 
3). Similarly, CD276 and ATP11A (ATPase phospholipid 
transporting 11A) were chosen as the represented target 
for miR-1207-5p (Table 3).
The expression levels of miR-296-5p or miR-1207-5p 
were 102 to 106-fold higher in PANC-1 cells transfected 
with their mimics compared with those in control cells, 
indicating high transfection efficiency (Fig. 3a). Similarly, 
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Fig. 3. Overexpression of miR-296-5p decreased BOK expression. 
a The expression levels of miR-296-5p or miR-1207-5p in PANC-
1, MIA PaCa-2, and PK-8 cells transected with each mimic were 
determined by TaqMan qPCR. b Levels of BOK mRNA in PANC-
1 cells transfected with miR-296-5p or control mimic were deter-
mined by TaqMan qPCR at 24 and 48 h after transfection. c BOK 
protein levels in transfectants of miR-296-5p or control mimic 
were determined by Western blotting at 24 and 48 h after transfec-
tion. miRNA, microRNA; BOK, Bcl2-related ovarian killer; MW, 
molecular weight.
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miR-296-5p and miR-1207-5p expression levels in MIA 
PaCa-2 and PK-8 cells transfected with their mimics were 
102 to 103-fold higher as compared with control cells, in-
dicating high transfection efficiency.
BOK mRNA levels in PANC-1 cells transfected with 
miR-296-5p mimic were decreased by 58% at 24 h and 
78% at 48 h compared with control cells (p < 0.01, respec-
tively; Fig.  3b). Likewise, MIA PaCa-2 and PK-8 cells 
transfected with miR-296-5p mimic showed decreases of 
85 and 70%, respectively, compared with control cells 
(p < 0.01 respectively; online suppl. Fig. S3a). BOK pro-
tein expression was also significantly decreased in PANC-
1 cells at 24 and 48 h after transfection with miR-296-5p 
mimic (Fig.  3c). There were no significant changes in 
NUMBL mRNA levels after transfection of cells with 
miR-296-5p mimic (online suppl. Fig. S3a). Moreover, 
the levels of CD276 and ATP11A mRNA in PANC-1 cells 
did not change significantly after transfection with miR-
1207-5p mimic (online suppl. Fig. S3b). Thus, it is evident 
that BOK could be a functional target of miR-296-5p in 
pancreatic cancer cells. It was also confirmed that a 
core  7-nucleotide sequence of mature miR-296-5p 
(GGGGCCC) matched 17 sites within the 3′-untranslat-
ed region of BOK (1732 bp) in the miRDB (online suppl. 
Fig. S4).
miR-296–5p Modulated Cell Invasion and EMT 
Properties
Since miR-296-5p was associated with poor survival 
in patients with PDAC, we first investigated the effect of 
miR296-5p on the invasion capability using transfec-
tants of miR-296-5p mimics. The invasion capability of 
PANC-1 and MIA PaCa-2 cells transfected with a miR-
296–5p mimic was significantly higher than that of cells 
transfected with a negative control mimic (Fig. 4a, p < 
0.01, respectively). Moreover, significantly higher inva-
sion capability was observed in PK-1 cells after transfec-
tion of miR296-5p mimics (online suppl. Fig. S5, p < 
0.01).
Next, we examined the role of BOK in cell invasion by 
knockdown of the gene using siRNA in MIA PaCa-2 cells. 
The level of BOK mRNA in MIA PaCa-2 cells transfected 
with siRNA targeting BOK was inhibited by 85%, al-
though the BOK mRNA levels in PANC-1 and PK-1 
transfectants were not inhibited efficiently, probably due 
to the low expression of miR-296-5p in these cell lines 
(data not shown). MIA PaCa-2 cells in which BOK was 
knocked down showed significantly enhanced cell inva-
sion compared with cells transfected with scrambled 
 siRNA (Fig. 4b, p < 0.05). These data strongly suggest that 
miR-296-5p enhances cell invasion ability through inhi-
bition of BOK.
Since cancer cell invasion is reportedly associated 
with EMT, we next investigated the expression of EMT-
associated proteins including E-cadherin, N-cadherin, 
and vimentin by Western blotting (Fig. 4c). The expres-
sion of E-cadherin in MIA PaCa-2 cells transfected with 
miR-296-5p mimic was slightly lower at 24 h and sig-
nificantly lower at 48 h as compared with control cells, 
while the expression of N-cadherin was similar or slight-
ly increased and the expression of vimentin was signifi-
cantly higher at 48 h. These results suggest that miR-296-
5p overexpression induces EMT in pancreatic cancer 
cells.
miR-296–5p Affected Drug-Induced Apoptosis by 
BOK Inhibition
We investigated whether miR-296–5p affects the 
drug resistance of PANC-1 cells to 5-fluorouracil (5-
FU) by Western blotting for caspase-9 (Fig. 5a). Addi-
tion of 5-FU to PANC-1 cells transfected with negative 
control mimic led to a significant increase in cleaved 
caspase-9 expression, suggesting 5-FU-induced apopto-
sis. However, cleaved caspase-9 expression in PANC-1 
cells transfected with 296-5p mimic was significantly 
lower, while caspase-9 expression in the transfectants 
was higher than that of control cells. Moreover, BOK 
protein expression in transfectants of miR-296-5p was 
decreased as compared with that of control cells. Similar 
results were obtained for MIAPaCa-2 cells transfected 
with miR-296-5p mimic; cleaved caspase-9 expression 
and BOK expression were lower than in control cells 
(online suppl. Fig. S6). These results suggest that miR-
296-5p induced drug resistance to 5-FU through inhibi-
tion of BOK expression in pancreatic cancer cells. We 
also examined the effect of miR-296-5p on gemcitabine 
(GEM) resistance in PANC-1 cells (online suppl. Fig. 
S7). Addition of GEM (30 µM) to PANC-1 cells trans-
fected with negative control mimic resulted in a signifi-
cant increase in cleaved caspase-9. In PANC-1 cells 
transfected with miR-296-5p, however, cleaved cas-
pase-9 expression and BOK expression were lower than 
in control cells. Thus, our data suggest that miR-296-5p 
induced drug resistance to 5-FU and GEM in pancre-
atic cancers.
The effect of miR-296-5p on cell proliferation in 
PANC-1 and MIA PaCa-2 cells was investigated by cell 
counting (Fig. 5b). No significant difference in prolifera-
tion was observed between each transfectant with miR-
296-5p mimic compared with control cells.
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Fig. 4. Cell invasion capability and EMT properties induced by 
transfection of miR-296-5p and knockdown of BOK. a The inva-
sion capability of PANC-1 or MIA PaCa-2 cells transfected with 
miR-296-5p or control mimic was determined using a CytoSelect 
24-well cell invasion assay kit. The invading cells were stained, 
lysed, and quantified by measuring OD at 560 nm. b The invasion 
capability of MIA PaCa-2 cells transfected with siRNA targeting 
BOK or control siRNA was determined using a CytoSelect 24-well 
cell invasion assay kit. Representative photographs of invading cells 
are shown at low magnification (i, iii) and the quantified results af-
ter extraction are presented as mean ± SD of the OD values obtained 
in triplicate (ii, iv). c Expression of the EMT-associated proteins 
 E-cadherin, N-cadherin, and vimentin were determined by West-
ern blotting before and 24 and 48 h after transfection. β-actin was 
used as a control. OD, optical densities; BOK, Bcl2-related ovarian 
killer; siRNA, small interfering RNA; MW, molecular weight.
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Discussion
We used an miRNA microarray to examine the ex-
pression profile of 2,042 miRNAs in micro-tissues ob-
tained by EUS-FNA from 13 unresectable advanced 
PDACs, and found significant correlations between the 
high expression of several miRNAs (e.g., miR-296-5p) 
and short survival times. Moreover, transfection of an 
miR-296-5p mimic into pancreatic cancer cell lines en-
hanced cell invasion and drug resistance with a transition 
to EMT, via inhibition of BOK as a target gene. This is the 
first report to analyze miRNA profiles of unresectable 
metastatic PDACs using EUS-FNA samples. Our results 
strongly suggest that miR-296-5p is a true prognostic bio-
marker for unresectable metastatic PDACs because we 
used unresectable metastatic PDAC tissue specimens for 
analysis in this study rather than surgically operated non-
metastatic PDAC tissues as were used in the majority of 
previous studies. Our results raise the possibility of using 
miR-296-5p as a serum prognostic biomarker for liquid 
biopsy, and also of developing a future therapy targeting 
miR-295-5p and BOK for unresectable metastatic PDACs 
with a poor prognosis.
The development of EUS-FNA has made it possible to 
easily obtain micro samples from pancreatic tumors, even 
when the tumor is surgically unresectable. Some studies 
have investigated miRNA expression in PDAC speci-
mens obtained by EUS-FNA [11, 21]; however, a limited 
number of miRNAs was analyzed by qPCR, and conse-
quently very little information was provided about the 
miRNA expression. To overcome these limitations, we 
used an unbiased approach with recently developed mi-
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Fig. 5. Anti-apoptosis and cell proliferation in PANC-1 cells trans-
fected with miR-296-5p. a Caspase-9 and cleaved caspase-9 were 
detected by Western blotting in PANC-1 cells transfected with 
miR-296-5p or control miRNA mimic (NC) treated with 5-FU. 
PANC-1 cells were transfected with miR-296-5p or control mimic 
and incubated with 20 mM 5-FU. The cells were then lysed and 
Western blot analysis was performed as described in the Materials 
and Methods section. BOK protein was analyzed using the same 
samples. β-actin was used as a control. Protein expression levels 
were quantified using Image J software. b The viability of PANC-1 
(i) and MIA PaCa-2 (ii) cells transfected with miR-296-5p or con-
trol mimic was determined using a Cell Counting Kit-8 at 6, 24, 48, 
72, and 96 h after transfection. Results are presented as mean ± SD 
of the OD value obtained in triplicate. 5-FU, 5-fluorouracil; MW; 
molecular weight; BOK, Bcl2-related ovarian killer; OD, optical 
densities. 
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croarrays (Sanger miRbase release 12.0) to measure glob-
al expression profiles of 2,042 miRNAs. In addition, al-
most all previous studies compared miRNA expression 
levels between PDAC specimens and normal pancreatic 
tissues or non-malignant pancreatic tissues such as those 
from patients with chronic pancreatitis. In contrast, our 
study focused on identifying miRNA-based prognostic 
biomarkers in unresectable PDACs, and found that miR-
296-5p, which targets BOK, was correlated with shorter 
survival. In this context, miR-296-5p would likely be a 
poor prognostic biomarker in patients with PDACs char-
acterized by metastasis, drug resistance, and EMT.
It has been reported that miR-296-5p acts as a cancer-
promoting miRNA in several types of malignant tumors 
[22–24]. Increased expression of miR-296-5p in breast 
and gastric cancers reportedly promotes cell proliferation 
by regulating transcription of certain genes or by activat-
ing signal transduction [23, 24]. Moreover, miR-296-5p 
has been reported to play an important role in promoting 
tumor progression in several types of cancer. In contrast, 
miR-296-5p was shown to serve as a tumor suppressor in 
prostate and lung cancer cells [25, 26]. These conflicting 
results have been explained by differences in the target 
genes among different types of cancer cells. In this study, 
we showed that miR-296-5p enhances cell invasion, mi-
gration, and drug resistance in association with EMT 
probably via inhibition of BOK, which acts as a tumor 
suppressor gene.
There has been only one study reporting altered ex-
pression of miR-296-5p in pancreatic neoplasia to date 
[12]. However, the function of miR-296-5p in pancreatic 
carcinogenesis remains unclear. In the current study, we 
showed that overexpression of miR-296-5p plays an im-
portant role in invasion, drug resistance, and EMT 
through inhibition of BOK function. BOK is a Bcl-2 fam-
ily protein with high homology to the pro-apoptotic pro-
teins (Bcl-2 associated X, apoptosis regulator) and (Bcl-2/
killer 1) [27]. It has been reported that transient transfec-
tion of BOK in CHO cells induced apoptosis via the clas-
sical apoptosis pathway involving the release of cyto-
chrome c, activation of caspase-3, and nuclear and DNA 
fragmentation [28, 29]. To obtain a better model in which 
cancer cell types can be compared, we performed gain-of-
function experiments using PANC-1 (low miR-296-5p 
expressing) and MIA PaCa-2 (high miR-296-5p express-
ing) cells. Effective transfections of miR-296-5p were per-
formed, which resulted in significant reduction of BOK 
expression in different types of cells. Furthermore, reduc-
tion of BOK expression inhibited caspase-3 activation in 
both types of pancreatic cancer cells. Known genetic mu-
tations, including those of TP53, KRAS, CDKN2A, and 
SMAD4, are important in the cascade of pancreatic carci-
nogenesis, but do not fully account for its aggressive be-
havior [30]. Thus, our data suggest that upregulation of 
miR-296-5p promoted PDAC progression, including 
metastasis and drug resistance, via inhibition of BOK 
function.
Only a few studies have reported that miRNAs pro-
mote EMT in PDACs. Zhang et al. [31] showed that over-
expression of miR-15b induced EMT by inhibiting 
SMURF2 in the pancreatic cancer cell line BxPC-3. More-
over, Wang et al. showed that upregulation of miR-935 
promoted EMT by inhibiting inositol polyphosphate 
4-phosphatase type I gene in the pancreatic cancer cell 
line HPDE6-C7 [32]. However, these studies focused only 
on miR-15b and miR-935, respectively, and did not exam-
ine miRNA profiles in pancreatic cancer tissues or pan-
creatic cancer cell lines. More importantly, their results 
are not supported by clinical data to confirm that the over-
expressed miRNA was correlated with survival in pancre-
atic cancer patients. It has also been reported that BOK 
inhibits EMT in lung cancer cell lines. In this context, it is 
even more plausible that miR-295-5p promotes EMT and 
enhances invasion capability and drug resistance via BOK 
inhibition, which was analyzed from the clinical survival 
data and miRNA profiles in patients with PDAC.
The tissue samples obtained by EUS-FNA in this study 
included non-cancerous stromal cells to some degree as 
well as cancer cells. That is, our miRNA data reflected the 
miRNA profile of not only cancer cells but also of stromal 
cells on some level. This is a weak point of the sample ac-
quisition method with EUS-FNA, and is a limitation of 
this kind of studies. Therefore, we have to take it into con-
sideration when interpreting our data. Moreover, the role 
of other miRNAs including miR-1207-5p in unresectable 
PDAC with a poor prognosis remains unclear. Therefore, 
the involvement of these miRNAs in advanced PDAC 
should be further investigated in future studies.
Conclusion
We comprehensively analyzed miRNA expression 
profiles in unresectable metastatic PDACs specimens ob-
tained by EUS-FNA, and we identified miRNAs with aber-
rantly high expression that were correlated with shorter 
survival. Moreover, the miR-296-5p/BOK signaling axis 
was closely associated with increased cell invasion, drug 
resistance, and EMT in PDACs. These data suggest that 
miR-296-5p expression is a useful biomarker for a poor 
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